Letter to Editor From Ishaq MU et al: "Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease".
作者信息
Ishaq Muhammad Umer, Fatima Noor, Sharif Rida, Awais Warda
机构信息
Nishtar Medical College, Nishtar Medical University, Punjab 66000, Pakistan.
出版信息
J Endocr Soc. 2024 Dec 13;9(1):bvae217. doi: 10.1210/jendso/bvae217. eCollection 2024 Nov 26.
Abstract
摘要
相似文献
1
Letter to Editor From Ishaq MU et al: "Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease".伊沙克·穆等人致编辑的信：“司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标”
J Endocr Soc. 2024 Dec 13;9(1):bvae217. doi: 10.1210/jendso/bvae217. eCollection 2024 Nov 26.
2
Response to "Letter to Editor From Ishaq MU et al: 'Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease'".对《Ishaq MU等人致编辑的信：“司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标”》的回应
J Endocr Soc. 2024 Dec 4;9(1):bvae218. doi: 10.1210/jendso/bvae218. eCollection 2024 Nov 26.
3
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease.司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标。
J Endocr Soc. 2024 Jul 8;8(8):bvae122. doi: 10.1210/jendso/bvae122. eCollection 2024 Jul 1.
4
Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.对霍洛维茨等人致编辑的信的回复，该信涉及达尔等人发表的“口服司美格鲁肽改善2型糖尿病患者的餐后血糖和脂质代谢，并延迟胃排空”一文。
Diabetes Obes Metab. 2021 Oct;23(10):2414-2416. doi: 10.1111/dom.14485. Epub 2021 Jul 28.
5
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.每周一次皮下注射司美格鲁肽可改善 2 型糖尿病患者的脂肪肝疾病：一项为期 52 周的前瞻性真实世界研究。
Nutrients. 2022 Nov 4;14(21):4673. doi: 10.3390/nu14214673.
6
Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.司美格鲁肽可改善患有代谢功能障碍相关脂肪性肝病的肥胖和2型糖尿病小鼠的肝脏脂肪变性及从头脂肪生成标志物。
Int J Mol Sci. 2024 Mar 4;25(5):2961. doi: 10.3390/ijms25052961.
7
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.司美格鲁肽与非酒精性脂肪性肝病合并2型糖尿病患者肝脏不良结局风险：一项多机构队列研究
Hepatol Int. 2025 Apr;19(2):395-404. doi: 10.1007/s12072-024-10752-9. Epub 2024 Nov 27.
8
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.一项评估 efinopegdutide 在非酒精性脂肪性肝病患者中的疗效和安全性的 IIa 期主动对照研究。
J Hepatol. 2023 Oct;79(4):888-897. doi: 10.1016/j.jhep.2023.05.013. Epub 2023 Jun 22.
9
The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease.司美格鲁肽联合二甲双胍对2型糖尿病合并非酒精性脂肪性肝病患者肝脏炎症和胰岛β细胞功能的影响。
J Diabetes Complications. 2025 Feb;39(2):108932. doi: 10.1016/j.jdiacomp.2024.108932. Epub 2024 Dec 9.
10
Semaglutide alters gut microbiota and improves NAFLD in db/db mice.司美格鲁肽改变肠道微生物群并改善 db/db 小鼠的非酒精性脂肪性肝病。
Biochem Biophys Res Commun. 2024 May 28;710:149882. doi: 10.1016/j.bbrc.2024.149882. Epub 2024 Apr 3.
引用本文的文献
1
Response to "Letter to Editor From Ishaq MU et al: 'Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease'".对《Ishaq MU等人致编辑的信：“司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标”》的回应
J Endocr Soc. 2024 Dec 4;9(1):bvae218. doi: 10.1210/jendso/bvae218. eCollection 2024 Nov 26.
本文引用的文献
1
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease.司美格鲁肽同时改善2型糖尿病和脂肪肝疾病患者的血管和肝脏指标。
J Endocr Soc. 2024 Jul 8;8(8):bvae122. doi: 10.1210/jendso/bvae122. eCollection 2024 Jul 1.
2
Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.司美格鲁肽联合恩格列净与单药治疗2型糖尿病非酒精性脂肪性肝病的疗效比较：一项随机临床试验的研究方案
PLoS One. 2024 May 3;19(5):e0302155. doi: 10.1371/journal.pone.0302155. eCollection 2024.
3
Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.在 II 期临床试验中使用司美格鲁肽治疗非酒精性脂肪性肝炎，对肝活检进行人工智能评分。
Hepatology. 2024 Jul 1;80(1):173-185. doi: 10.1097/HEP.0000000000000723. Epub 2023 Dec 19.
4
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.2型糖尿病患者中胰高血糖素样肽-1受体激动剂与严重肝脏事件的关联：一项斯堪的纳维亚队列研究。
Hepatology. 2024 Jun 1;79(6):1401-1411. doi: 10.1097/HEP.0000000000000712. Epub 2023 Dec 12.
5
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.新型 GLP-1 受体激动剂司美格鲁肽在减轻肥胖、非酒精性脂肪性肝炎和神经退行性疾病中的治疗潜力：叙事性综述。
Pharm Res. 2022 Jun;39(6):1233-1248. doi: 10.1007/s11095-022-03302-1. Epub 2022 Jun 1.
6
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
7
Glucagon-like peptide-1 receptor action in the vasculature.胰高血糖素样肽-1 受体在血管中的作用。
Peptides. 2019 Jan;111:26-32. doi: 10.1016/j.peptides.2018.09.002. Epub 2018 Sep 15.
8
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
Zotero 插件